- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02204670
EXIT: Prospective Study of the Response to Exercise (EXIT)
Exercise and Irisin Trial (EXIT): Prospective Cohort Study of the Determinants of the Metabolic Response to Exercise in Obese Adolescents
Background :
Regular exercise is a cornerstone in the prevention and the management of comorbidities. Unfortunately, the metabolic benefit of exercise training is not universal and varies among individuals. A main factor likely to explain the exercise training variability is the lack of empirical evidence on the determinants of exercise training. A series of muscle-derived cytokines have recently been discovered that (1) are released during exercise and (2) exert positive effects on peripheral tissues. Irisin is one of these novel "myokines" and might contributes to the metabolic adaptations to exercise training.
Methods:
The investigators will perform a pilot cohort study in which obese adolescents will perform resistance exercise training for 6 weeks. The main exposure variable will be the acute release of irisin during resistance exercise. The main outcome measures will be the change in hepatic triglyceride content and glucose area under the curve during a 75g, 2-hour oral glucose tolerance test.
Study Hypothesis:
The primary overall hypothesis is that the change in plasma Irisin with a single bout of exercise will be associated with the metabolic adaptations to 6 weeks of resistance training, specifically, the reductions in hepatic triglyceride content and post-prandial glucose excursions, in obese adolescents.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Winnipeg, Canada
- The Manitoba Institute of Child Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adolescents (12-18 years)
- Body mass index considered obese according to the International Obesity Task Force
Exclusion Criteria:
- Adolescents with medication-induced or type 1 diabetes
- are currently being treated with corticosteroids or atypical antipsychotics, as these agents significantly influence carbohydrate metabolism
- have an orthopaedic injury or chronic illness that would prevent them from performing the intervention
- have experienced >10% weight loss or enrolled in weight loss program within six months of enrolment
- a history of alcoholism or drug abuse
- require use of medication(s) known to affect insulin sensitivity or secretion within the last 30 days
- medication(s) known to cause weight gain
- anabolic steroids
- weight loss medication(s)
- pregnant or planning to be pregnant
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Overweight Adolescents Performing Resistance Training
Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period.
Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training.
This will be the primary exposure variable.
After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks.
During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
|
We will determine the amount of Irisin secreted after a single bout of resistance exercise.
Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise.
The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hepatic Triglyceride Content
Time Frame: 6 weeks
|
Hepatic triglyceride content will be measured by using 1H magnetic resonance spectroscopy.
After image acquisition, a single voxel volume of interest will be placed in the upper right lobe of the liver in an area devoid of adipose tissue to acquire 1H spectra.
A total of 64 spectra will be collected and averaged to determine the intracellular triglyceride content.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-prandial glucose
Time Frame: 6 weeks
|
Glucose area under the curve (AUC) will be determined by summing the area under serum glucose measures between each 15- or 30-min segment using the trapezium rule during a frequently sampled 75-g oral glucose challenge .
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jon M McGavock, PhD, University of Manitoba
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- B2014:064
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Fat
-
University of Eastern FinlandKuopio University HospitalCompleted
-
University of OxfordCompletedNAFLD | Fat; LiverUnited Kingdom
-
Wageningen UniversityCompletedNonalcoholic Fatty Liver Disease | Hepatic Fat AccumulationNetherlands
-
University of Wisconsin, MadisonNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingHealthy | Iron Overload | Liver FatUnited States
-
Istanbul Gelisim UniversityMarmara UniversityCompletedObesity | Liver Fat | Fatty Liver DiseaseTurkey
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Yonsei UniversityCompleted
-
Massachusetts General HospitalRecruitingFatty Liver | Liver Fat | Non-Alcoholic Fatty Liver Disease | Intermittent Fasting | Fatty Liver, NonalcoholicUnited States
-
Protein Supplies SLCompleted
-
University of California, San DiegoCompletedLiver Diseases | Liver Fat | Hepatic Steatosis | Non-Alcoholic Fatty Liver Disease | Nutritional and Metabolic DiseaseUnited States
Clinical Trials on Acute release of irisin after a single exercise session.
-
Instituto de Cardiologia do Rio Grande do SulCompleted
-
Riphah International UniversityCompletedCoronary Artery Bypass GraftPakistan
-
Riphah International UniversityCompleted
-
University of Kansas Medical CenterCompletedStroke | High Intensity Interval ExerciseUnited States
-
Université de SherbrookeEstrie University Integrated Health and Social Services Center - University...Recruiting
-
Ciusss de L'Est de l'Île de MontréalCompletedMusculoskeletal Pain Disorder | Spinal PainCanada
-
Centre Hospitalier Universitaire VaudoisCompletedPosttraumatic Stress Disorder | Intrusive Traumatic MemoriesSwitzerland
-
Ankara Diskapi Training and Research HospitalCompleted
-
Chipscreen Biosciences, Ltd.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Université de MontréalCanadian Institutes of Health Research (CIHR)Completed